Business Context and Reporting Period
Prothena Corporation plc filed its Form 10-K for the year ended December 31, 2013. The company is an Ireland-incorporated, clinical-stage biotechnology company developing monoclonal antibodies for amyloidosis, Parkinson’s disease and other synucleinopathies, inflammatory diseases and cancer. Its lead programs were NEOD001, PRX002 and PRX003. Prothena separated from Elan on December 20, 2012, so prior-period results are partly presented on a carve-out basis and may not be comparable to results as a standalone public company.
For fourth-quarter 2013, revenue was $0.167 million, operating expenses were $10.869 million, and net loss was $11.054 million, or $0.52 per share. The audited annual results below cover the full year.
Key Financial Metrics
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Related-party revenue | $0.676 million | $2.658 million | Down 75% |
| Research and development expense | $26.052 million | $34.139 million | Down 24% |
| General and administrative expense | $15.051 million | $9.929 million | Up 52% |
| Total operating expenses | $41.103 million | $44.068 million | Down 7% |
| Loss from operations | $(40.427) million | $(41.410) million | Improved $0.983 million |
| Net loss | $(40.996) million | $(41.411) million | Improved $0.415 million |
| Basic and diluted loss per share | $(2.20) | $(2.84) | Improved |
| Cash used in operating activities | $(32.098) million | $(42.072) million | Lower use of $9.974 million |
| Cash and cash equivalents | $176.677 million | $124.860 million | Up $51.817 million |
| Total liabilities | $9.140 million | $2.799 million | Up $6.341 million |
| Working capital | $170.816 million | $124.097 million | Up $46.719 million |
The filing does not disclose material interest-bearing debt. Liquidity consisted primarily of cash and cash equivalents, including $153.3 million in money market funds at year-end. The company reported no off-balance-sheet arrangements.
Revenue was insufficient to cover operating expenses; the filing does not present a meaningful positive operating or net margin. The company remains loss-making and had an accumulated deficit of $41.341 million at December 31, 2013.
Material Changes Versus the Prior Comparable Period
- Revenue declined because the scope of research and development services provided to Elan decreased.
- Research and development spending declined, primarily because of lower share-based compensation, personnel costs and external costs related to ELND005, discovery programs and NEOD001; spending increased for PRX002 and PRX003.
- General and administrative expense increased as Prothena incurred the costs of operating as an independent public company, including personnel and professional services.
- Net loss improved modestly despite the sharp revenue decline because total operating expenses decreased and interest income increased.
- Operating cash usage declined to $32.1 million, while cash increased by $51.8 million primarily due to the October 2013 equity offering.
- In October 2013, Prothena issued 4,177,079 new ordinary shares and received approximately $84.5 million in net proceeds. Janssen Pharmaceutical sold an additional 2,619,421 shares but Prothena received no proceeds from that secondary sale.
- NEOD001 entered a Phase 1 trial, with first patient dosing in April 2013. PRX002 was advanced toward clinical testing, and PRX003 was advanced into manufacturing and preclinical safety testing.
Guidance, Outlook, Commentary and Risks
- Management expected 2014 research and development expense to increase because of planned PRX003 manufacturing and toxicology work, a potential NEOD001 Phase 2/3 trial, and PRX002 development and manufacturing costs under the Roche collaboration.
- Management expected general and administrative expense to increase modestly in 2014 as the public-company infrastructure expanded.
- Management believed year-end cash would fund obligations for at least the next twelve months, but stated that additional capital would likely be required to continue development. Future financing could dilute shareholders or require unfavorable debt, licensing or collaboration terms.
- The Roche license agreement was signed in December 2013 and became effective in January 2014. Prothena received a $30.0 million upfront payment in February 2014 and expected a $15.0 million near-term clinical milestone payment in 2014. The agreement also provides potential development, regulatory and commercial milestones, royalties and U.S. profit-and-loss sharing.
- For U.S. Parkinson’s disease development and commercialization, Roche receives 70% and Prothena 30% of shared profits and costs if Prothena remains in the co-development arrangement. Roche is primarily responsible for development and commercialization after the PRX002 IND is filed, while Prothena retains certain co-development and co-promotion rights.
- Key risks include failure of clinical trials, regulatory delays or rejection, inability to obtain product supply from third-party manufacturers, dependence on Roche and other collaborators, uncertain patent protection, competition, reimbursement restrictions, product liability and the need for additional financing.
- Prothena relies on Boehringer Ingelheim for clinical supplies and has no internal manufacturing capacity. No material legal proceedings were reported.
Important Facts for Investors to Verify
- Verify the accounting treatment and revenue recognition for the Roche agreement, including the $30.0 million upfront payment and contingent milestone payments.
- Verify whether the $15.0 million Roche clinical milestone was achieved and received during 2014.
- Track NEOD001 Phase 1 safety, tolerability, dosing and progression to Phase 2/3 development.
- Track the timing and results of PRX002 Phase 1 development with Roche and the extent of Prothena’s future cost-sharing obligations.
- Assess cash burn, milestone receipts, equity issuance and the timing of any additional financing required to sustain operations.
- Consider the limited comparability of historical results because 2012 and earlier periods include Elan allocations and carve-out accounting.
- Monitor third-party manufacturing capacity, regulatory approvals, patent rights and Roche’s ability and willingness to continue development and commercialization.